Drug Trial Radar · NCT04728893
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
490
Planned (sponsor's estimate)
Start
Apr 5, 2021
Primary completion
Jan 4, 2029
Study completion Jan 4, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
Conditions
- Hematologic Malignancies
- Waldenstroms Macroglobulinaemia
- Non-Hodgkins Lymphoma
- Chronic Lymphocytic Leukaemia
Interventions
NemtabrutinibDrug
Nemtabrutinib tablets administered orally QD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of participants experiencing dose-limiting toxicities (DLTs)Time frame: Up to ~56 days (Cycles 1-2, cycle = 28 days)
- Part 1: Number of participants experiencing adverse events (AEs)Time frame: Up to ~71 months
- Part 1: Number of participants discontinuing study treatment due to AEsTime frame: Up to ~42 months
- Part 2: Objective Response Rate (ORR) per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 2018 as assessed by independent central review (ICR)Time frame: Up to ~61 months
- Part 2: ORR per Lugano criteria 2014 as assessed by ICRTime frame: Up to ~61 months
- Part 2: ORR per International Workshop on Waldenström's Macroglobulinemia (IWWM) criteria 2014 as assessed by ICRTime frame: Up to ~71 months
Locations
121 sites in 22 countries. Site status is shown where the registry gives one.
Highlands Oncology Group ( Site 2728)
Springdale, Arkansas · Recruiting
University of California San Diego Moores Cancer Center ( Site 2717)
La Jolla, California · Recruiting
Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site 2724)
Torrance, California · Completed
Colorado Blood Cancer Institute ( Site 2726)
Denver, Colorado · Recruiting
The University of Louisville, James Graham Brown Cancer Center ( Site 2729)
Louisville, Kentucky · Completed
Mayo Clinic - Rochester ( Site 2706)
Rochester, Minnesota · Active not recruiting
Astera Cancer Care ( Site 2732)
East Brunswick, New Jersey · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 2704)
Hackensack, New Jersey · Recruiting
Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 2708)
Fargo, North Dakota · Completed
UT Southwestern-Harold C. Simmons Cancer Center ( Site 2730)
Dallas, Texas · Recruiting
Medical Oncology Associates (Summit Cancer Centers) ( Site 2710)
Spokane, Washington · Recruiting
FUNDALEU ( Site 0104)
Caba, Argentina · Recruiting
Hospital Privado Universitario de Córdoba ( Site 0107)
Córdoba, Argentina · Recruiting
Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0110)
Mendoza, Argentina · Completed
Hospital Aleman ( Site 0102)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0103)
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Fundacion Estudios Clinicos ( Site 0112)
Rosario, Santa Fe Province, Argentina · Recruiting
Nepean Hospital-Nepean Cancer Care Centre ( Site 0204)
Sydney, New South Wales, Australia · Completed
Box Hill Hospital ( Site 0203)
Box Hill, Victoria, Australia · Recruiting
Sir Charles Gairdner Hospital ( Site 0200)
Nedlands, Western Australia, Australia · Recruiting
Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0300)
Rio de Janeiro, Brazil · Recruiting
BP - A Beneficencia Portuguesa de São Paulo ( Site 0302)
São Paulo, Brazil · Active not recruiting
Hospital Paulistano - Amil Clinical Research ( Site 0311)
São Paulo, Brazil · Recruiting
Hospital das Clinicas FMUSP-Pesquisa Clínica Hematologia ( Site 0303)
São Paulo, São Paulo, Brazil · Recruiting
Arthur J.E. Child Comprehensive Cancer Centre ( Site 0401)
Calgary, Alberta, Canada · Recruiting
The Ottawa Hospital ( Site 0404)
Ottawa, Ontario, Canada · Recruiting
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0406)
Toronto, Ontario, Canada · Recruiting
CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0403)
Montreal, Quebec, Canada · Recruiting
Jewish General Hospital ( Site 0400)
Montreal, Quebec, Canada · Recruiting
Anhui Provincial Hospital ( Site 2808)
Hefei, Anhui, China · Active not recruiting
Peking University Third Hospital-Hematology ( Site 2827)
Beijing, Beijing Municipality, China · Recruiting
The Second Affiliated Hospital of Chongqing Medical University ( Site 2825)
Chongqing, Chongqing Municipality, China · Completed
Sun Yat-sen University Cancer Center-Internal Medicine ( Site 2824)
Guangzhou, Guangdong, China · Active not recruiting
Liuzhou People's Hospital ( Site 2817)
Liuzhou, Guangxi, China · Recruiting
Guangxi Medical University Cancer Hospital ( Site 2814)
Nanning, Guangxi, China · Recruiting
Henan Cancer Hospital-hematology department ( Site 2802)
Zhengzhou, Henan, China · Recruiting
Wuhan Union Hospital ( Site 2816)
Wuhan, Hubei, China · Recruiting
The Second Xiangya Hospital of Central South University ( Site 2820)
Changsha, Hunan, China · Recruiting
Hunan Cancer Hospital ( Site 2822)
Changsha, Hunan, China · Recruiting
Jiangsu Province Hospital ( Site 2823)
Nanjing, Jiangsu, China · Recruiting
Showing 40 of 121 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.